Ask Dr. Ryan Sultan: 20 Common ADHD Questions Answered

ADHD - attention-deficit/hyperactivity disorder - is a neurodevelopmental condition defined by persistent, age-inappropriate inattention, hyperactivity, and impulsivity that begins in childhood and produces functional impairment across multiple settings such as school, work, and relationships. It affects approximately 5-7% of children and 4-5% of adults worldwide, with about 60-70% of childhood cases continuing to meet criteria or cause impairment in adulthood. ADHD is not literally a deficit of attention; it is a difficulty regulating attention, effort, and response inhibition, which is why people with ADHD can hyperfocus on engaging tasks while struggling with routine ones.

The condition is biological. Twin studies place heritability at 70-80%, neuroimaging shows consistent differences in frontostriatal circuits involved in executive function, and large registry studies link untreated ADHD with elevated risk of accidents, substance use, and premature mortality. ADHD is a clinical diagnosis based on standardized criteria and developmental history, not a personality style or a moral failing. For the full clinical overview see the ADHD guide.

ADHD is diagnosed clinically using DSM-5-TR criteria: a minimum number of symptoms of inattention and/or hyperactivity-impulsivity, onset before age 12, presence in two or more settings, and clear functional impairment not better explained by another condition. A complete evaluation typically takes 60-90 minutes and includes a structured developmental and psychiatric history, review of school or work records, validated rating scales such as the ASRS, Conners, or Vanderbilt, and screening for common comorbidities including anxiety, depression, obstructive sleep apnea, and substance use.

There is no blood test, brain scan, or computerized test that can diagnose ADHD on its own. QEEG and continuous performance tests can support but never replace clinical judgment. In children, collateral information from parents and teachers is essential; in adults, asking carefully about childhood symptoms is critical because adult-onset attention complaints without childhood history usually point to another diagnosis such as depression, sleep disorder, or thyroid disease. The structured natural-history framework is reviewed in detail in ADHD pharmacology and natural course.

Yes. ADHD is a lifespan condition, not a childhood phase. Longitudinal studies show that 50-70% of children with ADHD continue to meet full criteria or have clinically significant symptoms as adults, and population estimates put adult ADHD prevalence at approximately 4-5%. Adults often present differently than children: hyperactivity becomes internal restlessness rather than running around, and impulsivity shows up as interrupting, impulse spending, or career instability rather than climbing on furniture.

The DSM-5 shift to allow onset of symptoms by age 12 (rather than age 7 under DSM-IV) helped capture adults who had been missed as children, particularly women and people with predominantly inattentive presentations. Many adults are diagnosed only after a child of theirs is diagnosed and they recognize their own pattern. Adult ADHD is treatable; response rates to first-line stimulants in adults are roughly comparable to those in children, with effect sizes near 0.7. A reasonable first screen is the brief ADHD quiz, followed by full clinical evaluation.

Yes, and it is one of the most heritable conditions in all of psychiatry. Twin studies consistently estimate that 70-80% of variance in ADHD traits is explained by genetic factors, comparable to the heritability of height. If one parent has ADHD, each child has roughly a 40-50% probability of also having ADHD; full siblings of an affected child have about 30-35% recurrence risk. These are population estimates, not individual predictions.

The 2019 Psychiatric Genomics Consortium GWAS (Demontis et al., Nature Genetics) identified the first 12 genome-wide significant loci for ADHD across more than 55,000 individuals, and follow-up analyses have expanded that count to dozens of common variants of small effect, consistent with a polygenic architecture rather than a single ADHD gene. Heritability is not destiny: environment, early intervention, and treatment all meaningfully change developmental trajectories even in children with high genetic loading. The full evidence is in the post on ADHD genetics and heritability.

Yes, untreated ADHD is associated with substantially shortened life expectancy. The most cited estimate, from Russell Barkley's longitudinal research, suggests adults with persistent untreated ADHD lose roughly 8-13 years of life relative to peers, driven by accidents, suicide, cardiovascular risk factors, substance use, and poor adherence to medical care - not by ADHD biology itself. Danish registry data from Dalsgaard and colleagues (Lancet, 2015) found mortality rate ratios of approximately 2.07 in people with ADHD compared with the general population, with the highest excess risk in those diagnosed in adulthood.

Encouragingly, stimulant treatment has been associated with reduced all-cause mortality, lower rates of motor vehicle crashes, fewer criminal convictions, and decreased suicide attempts. The clinical implication is that ADHD treatment is not cosmetic; it changes the trajectory of long-term risk. The full data and clinical interpretation are reviewed in detail in ADHD and life expectancy.

Yes. ADHD medications are among the most extensively studied medications in psychiatry, with safety data extending more than 80 years for stimulants. Methylphenidate and amphetamines have effect sizes of 0.7-1.0 on core symptoms, larger than most psychiatric treatments. Common side effects include appetite suppression, sleep disruption, mild blood pressure or heart rate elevation, and transient mood changes; serious adverse events are rare in screened patients without preexisting cardiovascular disease.

Large studies, including Cooper and colleagues' NEJM analysis of more than 1.2 million stimulant-treated patients, found no increase in serious cardiovascular events at therapeutic doses in adults without preexisting heart disease. Non-stimulants such as atomoxetine, guanfacine, clonidine, and viloxazine provide additional options with different side effect profiles. Risk-benefit analysis consistently favors treatment for moderate-to-severe ADHD given the elevated mortality, accident, and substance use risks of leaving it untreated, as detailed in adverse outcomes of untreated ADHD.

The best ADHD medication is the one that works for the individual patient with the fewest side effects, but the evidence base places stimulants as first-line for most patients. Methylphenidate-class agents (Concerta, Ritalin, Focalin) and amphetamine-class agents (Adderall, Vyvanse, Mydayis) both have large effect sizes of 0.7-1.0 and roughly 70% individual response rates within class, meaning many patients who fail one class respond well to the other. Long-acting formulations are preferred for adherence and steadier symptom coverage across the day.

Non-stimulants including atomoxetine (Strattera), guanfacine ER (Intuniv), clonidine ER (Kapvay), and viloxazine (Qelbree) are reasonable choices when stimulants are contraindicated, poorly tolerated, or when comorbid anxiety, tics, or substance use is significant. Practical selection depends on age, comorbidities, prior trials, formulation preferences, and insurance coverage. The full landscape, including dosing principles and combination strategies, is in the ADHD medications guide.

Qelbree is the brand name for viloxazine extended-release, a non-stimulant ADHD medication approved by the FDA for children and adolescents in 2021 and for adults in 2022. Mechanistically, viloxazine is a selective norepinephrine reuptake inhibitor with additional serotonergic activity (5-HT2C agonism, 5-HT2B antagonism), differentiating it from atomoxetine. Pivotal trials showed statistically significant reductions in ADHD-RS-5 scores within one to two weeks of titration - faster than the typical 4-6 week onset of atomoxetine - with effect sizes of roughly 0.3-0.5, smaller than stimulants but clinically meaningful.

Qelbree is not a controlled substance, has no abuse potential, and is a useful option for patients with comorbid anxiety, substance use history, tics, or stimulant intolerance. Common side effects include somnolence, decreased appetite, headache, and fatigue, and there is a boxed warning regarding suicidal ideation in pediatric patients that warrants monitoring. Qelbree is discussed alongside other newer agents in the post on new ADHD medications in 2026.

Apparent loss of effect on a stable ADHD medication dose has several explanations, and true pharmacologic tolerance is only one of them - and probably the least common. More frequent causes include increased daily demands (a new job, exam season, parenting load), unrecognized sleep deprivation, undertreated comorbidities such as depression or anxiety, hormonal changes (perimenopause, postpartum), new medications that affect absorption or metabolism (proton pump inhibitors with amphetamine salts, acidic foods around dosing), increased caffeine or alcohol, and weight gain that has effectively reduced mg/kg dosing.

When pharmacologic tolerance does occur, the response is structured: confirm adherence and timing, optimize sleep and nutrition, consider a brief medication holiday, switch to the alternative stimulant class (methylphenidate to amphetamine or vice versa, which crosses about 30% non-responders), or add or rotate a non-stimulant. Patients should not silently double their dose. The systematic clinical approach is detailed in the post on ADHD medication tolerance.

For most patients, stimulants are more effective. Stimulants produce effect sizes of approximately 0.7-1.0 on core ADHD symptoms, while non-stimulants cluster around 0.3-0.6. Stimulants also work within hours to days, whereas atomoxetine and viloxazine typically take two to six weeks to reach full effect. That said, better-on-average does not mean better-for-every-patient. Non-stimulants are preferred when there is a history of substance use disorder, when stimulants have caused intolerable anxiety, insomnia, cardiovascular concerns, or tics, in patients with comorbid anxiety where atomoxetine may treat both conditions, or when controlled substance access is a household concern.

Many real-world treatment plans combine a stimulant for daytime coverage with a non-stimulant such as guanfacine ER for evening regulation, emotion modulation, and sleep onset. The decision is individualized, weighing comorbidities, prior response, side effect tolerance, and patient preference. The full clinical pharmacology framework, including the natural-course rationale for early treatment, is on the ADHD pharmacology and natural course page.

Stimulant ADHD medications produce small, predictable increases in heart rate (typically 3-10 bpm) and blood pressure (2-5 mmHg) at therapeutic doses, but the evidence does not support a meaningful increase in serious cardiovascular events in patients without preexisting heart disease. Cooper and colleagues (NEJM, 2011) examined more than 443,000 stimulant-exposed adults and Cooper, Habel, and colleagues studied over 1.2 million children and young adults, finding no increased risk of serious cardiovascular events relative to non-users.

Current AHA guidance recommends a careful cardiac history and physical examination before initiating stimulants, with ECG reserved for cases where history suggests risk. Patients with structural heart disease, uncontrolled hypertension, serious arrhythmias, or cardiomyopathy require cardiology co-management or non-stimulant alternatives. For the average patient with ADHD, the risk-benefit balance strongly favors treatment because untreated ADHD carries its own meaningful mortality through accidents and suicide. The full evidence map is in the post on ADHD cardiovascular safety.

ADHD medications in pregnancy involve trade-offs that should be individualized, not blanket-prohibited. The largest observational studies, including Danish and U.S. registry analyses of tens of thousands of stimulant-exposed pregnancies, have generally not found substantial increases in major congenital malformations, with absolute risk differences under 1% when adjusted for confounders such as maternal age, substance use, and comorbid psychiatric illness. Some analyses suggest small associations with preeclampsia, preterm birth, and modestly reduced birth weight, though residual confounding by ADHD itself is hard to fully exclude.

The clinical question is not whether stimulants carry zero risk - they do not - but whether their risk exceeds the risk of untreated ADHD during pregnancy, which includes motor vehicle crashes, occupational impairment, mood worsening, and difficulty preparing for an infant. Many patients with moderate-to-severe symptoms continue medication after shared decision-making; others taper, particularly in the first trimester. The post on ADHD in pregnancy and postpartum covers the data and decision framework in detail.

Estrogen modulates dopaminergic and prefrontal cortical function, which directly impacts ADHD symptom severity across the female lifespan. During perimenopause - typically the late thirties to early fifties - estrogen levels fluctuate unpredictably and then decline, and women frequently report a sharp worsening of inattention, working memory failures, and emotional dysregulation that is often misattributed to normal aging, depression, or anxiety. A 2024 survey of women with ADHD found that more than 70% reported worsened symptoms during perimenopause, and many required dose increases or a switch to a longer-acting formulation.

Clinicians familiar with the pattern recognize it; clinicians unfamiliar with it often miss it. Treatment options include optimizing the existing ADHD medication regimen, evaluating for hormone replacement therapy when otherwise appropriate, treating coexisting sleep disturbance, and screening for the iron and thyroid abnormalities common in this age group. The pattern, and the way it interacts with prior late diagnosis in women, is covered in ADHD in perimenopause and menopause and on the broader ADHD in women page.

ADHD and anxiety share inattention, restlessness, sleep problems, and difficulty concentrating, but the phenomenology differs. In ADHD, attention drifts because the brain disengages from low-stimulus tasks; in anxiety, attention is captured by worry. ADHD inattention is present from childhood and is relatively content-free; anxious inattention typically has identifiable worry content and worsens with stress or anticipatory cues. Approximately 25-40% of adults with ADHD have a comorbid anxiety disorder, so the clinical question is often not either/or but in what proportion.

A careful history asking when symptoms started, whether they occur even in calm low-stakes settings, and whether there is identifiable anxious thinking content usually clarifies the picture. Treatment ordering matters: treating ADHD first often reduces secondary performance anxiety, whereas in primary anxiety disorders SSRIs and CBT are first-line. Some patients require both. A reasonable starting point is the brief ADHD quiz, followed by full clinical evaluation that screens explicitly for anxiety, depression, and sleep disorders.

Untreated obstructive sleep apnea is a major mimic of ADHD in both children and adults, producing inattention, irritability, hyperactivity (in children), and executive dysfunction that responds dramatically to treatment of the underlying breathing disorder. Obstructive sleep apnea affects roughly 10-30% of adults depending on the population studied, and in adults with new or worsened attention complaints it deserves explicit screening with a tool such as the STOP-BANG questionnaire and, when indicated, polysomnography.

Clinical red flags include adult-onset attention complaints without a childhood history of ADHD symptoms, loud snoring, witnessed apneas, morning headaches, obesity, large neck circumference, and treatment-resistant hypertension. In children, adenotonsillar hypertrophy can produce nighttime obstruction that drives daytime hyperactivity, and adenotonsillectomy resolves the apparent ADHD in a meaningful subset of cases. The two conditions also co-occur, so finding apnea does not rule out ADHD. The full diagnostic logic and case examples are in the post on ADHD vs. sleep apnea.

Time blindness is a colloquial term for the temporal processing deficits that are core to ADHD: difficulty perceiving the passage of time, estimating how long tasks will take, anticipating future deadlines as emotionally real, and resisting present-moment distraction in service of distant goals. Russell Barkley and others have framed ADHD as fundamentally a disorder of self-regulation across time, mediated by prefrontal-striatal circuits responsible for working memory and delay discounting.

Time blindness shows up clinically as chronic lateness, missed deadlines, last-minute scrambles even on important tasks, surprise that several hours have passed during a screen session, and emotional difficulty acting on consequences more than a few days in the future. It is the mechanism behind much of what is mislabeled as laziness or irresponsibility in untreated ADHD. Stimulant treatment improves temporal estimation in laboratory tasks, and external scaffolding (visible analog timers, calendars, structured routines) compensates for the underlying deficit. The full clinical picture is reviewed in the post on ADHD time blindness.

ADHD masking is the often-unconscious effort to suppress or camouflage ADHD symptoms to meet social and professional expectations - by mimicking neurotypical behavior, over-rehearsing conversations, building elaborate compensatory systems, and concealing the cost. Masking is more common in women, in late-diagnosed adults, and in people who grew up in high-expectation environments where ADHD symptoms drew strong negative attention. Although masking can produce apparent functioning, it is metabolically expensive: studies of related phenomena in autism suggest masking is associated with elevated burnout, anxiety, depression, and identity confusion.

Clinically, masking is one major reason ADHD is missed in women and in high-achieving adults, because the very pattern that produces internal suffering also produces external composure. Unmasking is gradual, involving selectively letting accommodations show, redesigning environments to remove the most expensive compensations, and recovering authentic preferences for pacing, sensory load, and social rhythm. The pattern is covered in detail in the post on ADHD masking and unmasking.

Yes - exercise has meaningful but adjunctive benefit for ADHD symptoms. It is not a substitute for medication in moderate-to-severe cases. Meta-analyses of randomized exercise trials in children and adults with ADHD show small-to-moderate effect sizes of approximately 0.4-0.6 on attention, executive function, and behavioral symptoms - smaller than first-line stimulants (0.7-1.0) but clinically valuable, especially in combination with medication. The biological rationale is solid: acute aerobic exercise transiently increases dopamine and norepinephrine availability in the prefrontal cortex, mimicking part of the mechanism of stimulant medication.

Chronic exercise upregulates BDNF and supports prefrontal structural integrity. Practical clinical recommendations include 30-45 minutes of moderate aerobic activity most days, ideally before cognitively demanding work, with the form of exercise mattering less than consistency. Combining exercise with medication produces additive benefit in observational data. The full evidence review, including dose-response and the comparison with mindfulness and CBT, is in the post on exercise and ADHD evidence.

Omega-3 supplementation, particularly with combined EPA and DHA, produces small but statistically significant improvements in ADHD symptoms in randomized trials and meta-analyses, with effect sizes of approximately 0.2-0.3 - smaller than stimulants by a factor of roughly three to five. The strongest signal is for EPA-predominant formulations at doses of approximately 1-2 grams daily of combined EPA+DHA for at least 8-12 weeks. Omega-3s are reasonable to consider in mild ADHD, as an adjunct to standard treatment, or for families seeking nutritional optimization, and they have an excellent safety profile aside from mild GI effects and theoretical bleeding risk at very high doses.

They are not a substitute for evidence-based medication in moderate-to-severe ADHD. Other widely marketed supplements - zinc, iron, magnesium, ginkgo, ginseng - have weaker or inconsistent evidence and should be used selectively, typically only with documented deficiency on lab testing. Megadosing carries real risks. The full evidence map, including what to ignore, is in the post on ADHD diet and supplements.

Finding a qualified ADHD psychiatrist in New York City is a matter of credentialing, fit, and access. Look for board certification in adult psychiatry, and for children additional board certification in child and adolescent psychiatry; meaningful clinical experience treating ADHD across the lifespan; and willingness to assess and treat common comorbidities including anxiety, mood, sleep, and substance use. Both academic medical centers (Columbia, NYU, Mount Sinai, Weill Cornell) and high-quality private practices serve NYC patients, with trade-offs in wait time, insurance acceptance, and continuity of care.

Telepsychiatry is now well established for ADHD care and works well for stable patients, with DEA rules requiring in-person evaluation in some circumstances for controlled substance prescribing. Verify state licensure, malpractice history through the New York Office of the Professions, and reviewable credentials such as ORCID and NPI numbers. A practical starting point is the page on ADHD psychiatrist NYC, and patients weighing the cost of not getting care should also see adverse outcomes of untreated ADHD.